Lineage Capital Surpluse from 2010 to 2025

LCTX Stock  USD 0.63  0.05  7.35%   
Lineage Cell Capital Surpluse yearly trend continues to be fairly stable with very little volatility. Capital Surpluse will likely drop to 6,109 in 2025. During the period from 2010 to 2025, Lineage Cell Capital Surpluse regression line of annual values had r-squared of  0.57 and arithmetic mean of  28,742. View All Fundamentals
 
Capital Surpluse  
First Reported
2010-12-31
Previous Quarter
6.4 K
Current Value
6.1 K
Quarterly Volatility
38.9 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lineage Cell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lineage Cell's main balance sheet or income statement drivers, such as Depreciation And Amortization of 922.5 K, Interest Expense of 6 M or Total Revenue of 10.8 M, as well as many indicators such as Price To Sales Ratio of 22.99, Dividend Yield of 0.0015 or PTB Ratio of 2.8. Lineage financial statements analysis is a perfect complement when working with Lineage Cell Valuation or Volatility modules.
  
Check out the analysis of Lineage Cell Correlation against competitors.

Latest Lineage Cell's Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Lineage Cell Therapeutics over the last few years. It is Lineage Cell's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lineage Cell's overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Lineage Capital Surpluse Regression Statistics

Arithmetic Mean28,742
Geometric Mean13,386
Coefficient Of Variation135.33
Mean Deviation32,615
Median7,145
Standard Deviation38,897
Sample Variance1.5B
Range87.9K
R-Value(0.75)
Mean Square Error697.8M
R-Squared0.57
Significance0.0007
Slope(6,165)
Total Sum of Squares22.7B

Lineage Capital Surpluse History

2025 6108.98
2024 6430.5
2014 7145.0

About Lineage Cell Financial Statements

Lineage Cell investors use historical fundamental indicators, such as Lineage Cell's Capital Surpluse, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lineage Cell. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse6.4 K6.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lineage Stock Analysis

When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.